1. Home
  2. DOGZ vs IPHA Comparison

DOGZ vs IPHA Comparison

Compare DOGZ & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DOGZ

Dogness (International) Corporation

N/A

Current Price

$1.60

Market Cap

153.5M

ML Signal

N/A

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

N/A

Current Price

$1.55

Market Cap

160.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
DOGZ
IPHA
Founded
2003
1999
Country
China
France
Employees
N/A
174
Industry
Miscellaneous manufacturing industries
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
153.5M
160.7M
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
DOGZ
IPHA
Price
$1.60
$1.55
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$5.00
AVG Volume (30 Days)
205.5K
15.5K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$28.31
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.02
$1.46
52 Week High
$34.53
$2.63

Technical Indicators

Market Signals
Indicator
DOGZ
IPHA
Relative Strength Index (RSI) 30.39 38.70
Support Level $1.36 N/A
Resistance Level $1.71 $1.88
Average True Range (ATR) 0.14 0.08
MACD 0.29 -0.01
Stochastic Oscillator 82.86 26.47

Price Performance

Historical Comparison
DOGZ
IPHA

About DOGZ Dogness (International) Corporation

Dogness (International) Corp designs, manufactures pet products, including leashes and smart products, and lanyards. The company designs, processes, and manufactures fashionable and high-quality leashes, collars, and harnesses to complement cats' and dogs' appearances, as well as intelligent pet products. The company also provides dyeing services to external customers, as well as pet grooming services. The dyeing service is to utilize the existing production capacity and the pet grooming service is immaterial. Geographically, it generates maximum revenue from Mainland China and also has a presence in the United States, Europe, Australia, Canada, Central, and South America, Japan, and other Asian countries and regions.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.

Share on Social Networks: